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Centralized banking of human embryonic stem (hES) cells is an endeavor that can benefit individual research
efforts and enhance international collaboration but is complicated by the fact that the science is rapidly
evolving in an environment of heterogeneous laws, guidelines, and ethical standards. Written from the van-
tage point of regulatory professionals, this article provides an overview of the benefits of and challenges
facing hESC banking enterprises in general with a focus on a global centralized banking effort.Introduction
Would it not be grand if hESC researcherswere able to locate and
obtain hESC lines that had clearly documented and approved
ethical provenance, that were meticulously characterized, and
that met recognized standards for purity, safety, and predictabil-
ity? This lofty goal has been identified by investigators (Brivanlou
et al., 2003) and included in the existing guidelines from the Inter-
national Society for Stem Cell Research (2007) (ISSCR) and rec-
ommendations from other bodies such as the U.S. National
Academy of Sciences (2005) (NAS) and the British government.
The ISSCR Guidelines state the following: ‘‘Hand in hand with
the privilege to perform derivations is the obligation to distribute
the cell lines to the research community. A clear, detailed outline
for banking and open access to the new lines should be incorpo-
rated into derivation proposals. New pluripotent stem cell lines
should be made generally available as soon as possible follow-
ing derivation and first publication. The ISSCR encourages re-
searchers todeposit linesearly into centralized repositorieswhere
the lineswill beheld for releaseanddistributionuponpublication.’’
This is a virtual call to action—a call for the creation of central-
ized repositories or banks. But what exactly is the desired out-
come?And,more importantly,whatcan reasonably beachieved?
Agreement regarding the terms ‘‘bank’’ and ‘‘centralized’’ is
a necessary starting point. For the purposes of this document,
a bank is an entity that procures, stores, possibly processes,
and then distributes materials. The term centralized means ‘‘to
bring to a center; to concentrate by placing power and authority
in a center or central organization’’ (Webster’s Dictionary). In
centralized banking, acceptance of centralized control is a key
component. It is also important to note that centralized banking
may not necessarily refer to a central physical location for the
bank (although that might be the case); it may also refer to
centralizing the operation, administration, and enforcement of
standards for a bank that is physically dispersed.Implementing these definitions into practice is possible
through a variety of designs including (1) a single physical global
bank that sets rules and conditions regarding all aspects of
hESC acquisition, storage, maintenance, and dispersal; (2) a
limited number of regionalized physical banks; or (3) numerous
local physical banks. In the model of multiple banks, there
must be clear delineation of which centrally based rules of oper-
ation and quality control would bemandated, and whether or not
regional and local banks would have some degree of autonomy
on select issues. Each of these approaches has merit, and each
presents distinct logistical challenges.
It has also been suggested that, rather than working toward
centralized banks, efforts should focus on the creation of a cen-
tralized registry. A registry would provide, in a shareable format,
vital information regarding the hESC lines held by different enti-
ties. This transparency would seemingly facilitate access to and
sharing of hESC lines. In fact, such stem cell registries are being
established and are valuable adjuncts to any banking enterprise.
The EuropeanHumanEmbryonic StemCell Registrywas publicly
launched inJanuary2008 (http://hescreg.charite.de/typo3/index.
php?id=27). Another registry, part of the International Stem Cell
Initiative (ISCI) Project of the International Stem Cell Forum
(ISCF, http://www.stemcellforum.org/), is a global stemcell regis-
try of data on approximately 60 hESC lines contributed by 20
laboratories (Andrews, 2007). The ISCI is a global enterprise cur-
rently comprising 21 funders of stem cell research sharing the
belief that ‘‘international collaboration and information sharing
will accelerate progress and improve global practice in stem cell
research’’. Registries will also inform the scientific community of
the various standards being applied to this research, and this
opendisclosuremaywell encourage standardizedbenchmarking
for the derivation and handling of hESCs. But unlike a centralized
bank, a registry does not manage the complex logistics of main-
taining, propagating, and distributing hESC lines.Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 307
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this article on the goal of establishing a global banking enterprise
comprised of a number of national and/or regional hESC banks
that aim to provide researchers with quality hESC lines. This goal
seems to be in concordancewith the international research com-
munity, although there is no consensus on exactly what this
global enterprise should look like.
The scope of this article is to provide an overview of the
benefits and challenges of this vision, and not to present a spe-
cific working model of centralized banking or to discuss how to
address specific scientific technical details.
This article includes (1) an outline of the general benefits that
banking hESC lines offers individual researchers and research
institutions, and the specific benefits that centralized banking
would offer the global hESC research community; (2) a brief
overview of current banking activities and how this could fit
into a global banking scenario; and (3) a discussion of the chal-
lenges related to establishing hESC banks in general and,
more specifically, to a centralized banking effort. While the focus
is centralized banking, much of this overview can also inform
institutions that are grappling with establishing local repositories.
Why a Bank?
Human embryonic stem cells (hESCs) are pluripotent cells that
have the ability to give rise to all of the different cell types in
the human body. As such, they present vast potential to provide
new insight and new research tools that will hopefully someday
support new clinical applications. Excitement over the potential
of hESC research has increased the demand for a reliable source
of these cells. Investigators have two options: they can derive,
validate, expand, and store their own hESC lines or obtain an
existing hESC line from another source. The derivation process
requires specialized skills and expertise and invites much ethi-
cal, regulatory, and legal angst. While some investigators are
interested in the derivation process itself, many simply want
access to reliable and well-characterized hESC lines. Because
hESCs are able to self-propagate, they are a renewable resource
that lends itself to sharing. But researchers appropriately
demand lines that are scientifically and ethically robust. Investi-
gators need to be assured that the lines they use in their research
have been cultured, expanded, and maintained according to
most current accepted standards; that the lines meet criteria
for determining pluripotency; that they have been screened for
purity and safety; and that they were obtained in compliance
with appropriate ethical and legal standards.
While an investigator pursuing derivation of hESC lines can
clearly make his/her hESCs available to another investigator,
such one-to-one transactions have downsides for both the pro-
vider and the requestor. Many researchers deriving hESCs are
willing to share cell lines but find the process too resource inten-
sive. The person sharing the cells must (1) produce adequate
numbers of cells to share; (2) document the authenticity, purity,
safety, and stability of the product they are providing; (3) provide
documentation of provenance; and (4) deal with any locally
required material transfer agreements. These myriad tasks
require specialized training, expertise, materials, equipment,
and personnel. Many decide that their time, expense, and effort
would more productively be applied to the research itself. From
the perspective of the requestor, dealing with multiple distinct308 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.sources of hESCs requires due diligence with each provider
regarding the acceptability of the provenance and biologic qual-
ity of each cell line. A bank working as a third party and existing
primarily for the purpose of procuring and providing hESCs
makes sense for both providers and requestors. A bank can
achieve an economy of scale that benefits both parties by pro-
viding cell lines that adhere to the highest accepted biologic
standards and that have detailed documentation of provenance.
A centralized banking effort, if successful, would be used by
the majority of researchers who are deriving hESCs; therefore,
the bank would ideally include most of the hESC lines available
for sharing. This would increase not only the raw number of lines
available for research but also the genetic diversity of available
hESC lines by including hESCs that reflect various ethnic groups.
In addition, there would be a tremendous benefit to banking
hESC lines with disease-associated mutations; for example,
lines that have been derived from embryos that have been deter-
mined through preimplantation genetic diagnosis (PGD) to have
target mutations (Ben-Yosef et al., 2008) or from embryos devel-
oped through nuclear transfer (NT) using somatic cells from indi-
viduals who have the genetic defect associated with the disease
to be studied. (U.S. National Academy of Sciences, 2005).
While the current focus is on research-quality hESCs, the de-
mand for clinical-quality hESCs is rapidly approaching. In fact,
some feel that it is here already (Crook et al., 2007). The additional
and more stringent regulations for developing and maintaining
clinical-level materials, while perhaps daunting for the individual
researcher, can more easily be addressed in a centralized sys-
tem. Prominent researchers (Taylor et al., 2005; Nakajima et al.,
2007) have conjectured that banks could ultimately include and
makeavailable clinical-grade hLA-typedhESCcells. Thebenefits
of such banks, should they come to pass, could be enormous.
The Current Landscape
The UK Stem Cell Bank (http://www.ukstemcellbank.org.uk/) is
clearly the banking leader, with robust and transparent policies
to assure the biological quality and ethical sourcing of its cell
lines, and an impressive Phase II plan with an international scope
to be completed by 2010. The UK bank currently offers the inter-
national hESC community access to eight hESC lines and
reports that 12 more lines are due for release and 16 additional
lines have been ‘‘accessioned.’’ However, these 36 lines repre-
sent only a fraction of the number of hESC lines that have been
derived to date. An overview of stem cell research published in
June 2006 (Guhra et al., 2006) found evidence in the literature
of 414 existing hESC lines, and there may be many more unpub-
lished lines. Where are these lines, and why is this information
unavailable? Does this suggest that researchers are not ‘‘buying
in’’ to the idea of centralized hESC banking? Or is this a reflection
of the limited understanding of and access to centralized
banking and/or registries?
A centralized banking enterprise would benefit from interna-
tional standards for all aspects of hESC derivation, cell culture,
and characterization. This goal will be difficult to realize, given
the variety of techniques being utilized and the lack of consensus
regarding superiority of one practice over others. But there is
some progress being made. The ISCF, with 21 international
stakeholdermembers, has created the ISCI project spearheaded
by Peter Andrews of the University of Sheffield. Andrews
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vide the openness, reliability, and the ability for scientists to
reproduce and extend each other’s work, which are all crucial
to international collaborations between stem cell scientists.
This type of initiative is only possible through an organization
like the Forum which brings together funders and labs from
across the world, all driven by the desire to progress cautiously
while benefiting from the huge potential to be derived from
working together.’’
In June 2007, the Initiative published its first milestone—the
characterization of 59 hESC lines, including the profiling of 93
different genes (Andrews, 2007). The identified markers can
serve as a reliable, common standard to validate hESCs. More
than80 investigators from17 laboratories in 11different countries
participated in this effort. This bodeswell for a ‘‘buy in’’ to thecen-
tralized banking enterprise. The Initiative’s next project will focus
on culture media. Other challenges to be addressed include the
following: determination of the most suitable cryopreservation
methods for both stable long-term storage and for shipping,
and the harmonization of ethics in order to facilitate international
transfer of cells. This latter goal of harmonization of ethics is
particularly difficult in that it will have to address the vast range
of ethical and regulatory approaches being followed in different
countries and localities. (For an overview of a new initiative by
the ISCF toward the development of an international consensus
for hESC banking guidelines, see Healy et al. [2008] in this issue
of Cell Stem Cell.)
Another group, The Stem Cell Network of the Asia-Pacific
(SNAP) region, is a new coalition with representatives from
Australia, China, India, Japan, Korea, Singapore, Taiwan, and
Thailand that has sited as one of its areas of interest ‘‘best prac-
tices for cell processes and banking, and methods for culture
and differentiation of hES cells’’ (Sipp, 2007). Members of this
regional coalition overlap with those of the ISCI and can help
form the framework for a global banking initiative.
The burgeoning number of stem cell journals, stem cell confer-
ences, and stem cell training opportunities point to the collabora-
tive natureof the stemcell community. Asmuchof this attention is
focused on sharing advancements in hESC technology, there is
cause for optimism that the challenges facing banking are being
met head on and the community will indeed buy in to centralized
efforts.
Existing hESC Banks
Currently there are a number of operational banks. A brief over-
view of some of these banks will provide some background to
inform how existing banksmight or might not fit into a centralized
banking framework. A subsequent discussion will detail chal-
lenges faced in creating and implementing hESC banking pro-
cedures for widespread use in the current international arena.
Public Banks
The UK Stem Cell Bank is the best known and most established
repository for hESCs. Although hosted by the UK’s National
Institute for Biological Standards and Control (NIBSC), a publicly
funded scientific organization, the bank aims to be an interna-
tional resource for all stem cell researchers to deposit and
access ethically sourced and well-characterized hESC lines. In
addition to the bank’s capability to access and distribute ‘‘re-
search grade’’ lines, a great deal of time, care, and money hasalready been spent to ready the facility to receive and distribute
clinical-grade hESC lines that conform to British and U.S. regu-
latory requirements for transplantation into humans. The bank’s
policy of transparency makes for easy access to its policies and
processes online (Healy et al., 2005).
TheUnitedStatesNationalStemCellBankhasbeenestablished
by the National Institutes of Health (NIH) and is hosted by WiCell
Research Institute, a nonprofit supporting organization of the Uni-
versity of Wisconsin-Madison (http://www.nationalstemcellbank.
org/). Its purpose is to acquire, characterize, andglobally distribute
the 21 hESC lines and their subclones that are listed on the NIH
Human Embryonic Stem Cell Registry. Lines listed on the NIH
registryare theonlyhESC lines that canbeused in federally funded
research in the United States.
Other national and regional stem cell banks have been or are
being created in a number of countries including Australia, South
Korea, andSpain (Nieto et al., 2006). Thesebanks face hurdles, as
evolving regional and national laws make it difficult to formalize
operational procedures for their specific banks. For example,
Spain’s public hESCbankwas the subject of lawsuits (sincedrop-
ped) regardingcompeting local andnational lawsgoverninghESC
research activity,which reflected underlyingdissonance between
the ruling governments in Spain and Andalusia (an autonomous
community of Spain) on the ethics of this type of research (Fuchs,
2004). The politicalization of hESC research, not unique to Spain,
is a reflection of the controversial nature of this research and a
widespread challenge to nations, regions, and localities attempt-
ing to establish policies related to in this research.
Public banks, accountable to their constituencies, are well
positioned to be regional arms of a global banking enterprise.
Nations active in hESC research are currently showing their com-
mitment to international collaboration in a variety of ways, so the
growth and cooperation of public banks will be an essential
ingredient of a centralized banking enterprise.
Institutional Banks
At the local level, academic research institutions conducting
hESC research may house hESC banks to store stem cells de-
rivedor acquired by their own institutions. Theymayhave core fa-
cilities that process,maintain, store, anddistribute hESCs to local
investigators. These banks are needed at the local level and can
serve as feeders into a physically centralized banking effort.
Commercial Banks
Private industry engaging in stem cell research has its own hESC
banks, which may or may not distribute the lines externally.
Some examples are the following.
Advanced Cell Technology (ACT, http://www.advancedcell.
com/), a biotechnology company that has published peer-
reviewed articles on its work, has been working with the U.S.
Food and Drug Administration (FDA) in preparation for filing
Investigational NewDrug (IND) applications to begin clinical trials
for the reparation of blood vessels and for the treatment of mac-
ular degeneration using hESC-derived cells. ACT has opened
two facilities capable of culturing and expanding hESC lines.
Each facility has a ‘‘master bank’’ of hESC lines and ‘‘working
banks’’ of hESC-derived differentiated stem cells (see ACT).
The StemRide International Limited (SIL) website (http://www.
stemride.com/) states that it has a bank of more than 100 hESC
lines including 20 lines with genetic or chromosomal abnormali-
ties for distribution to international stem cell researchers. TheCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 309
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in vitro fertilization (IVF) clinic, provides these lines for a fee. Its
website does not provide the transparency of the public stem
cell banks, and informationon these lineshasnotbeenpublished.
Stem cell banks that are sponsored by the competitive
biotechnology industry are naturally proprietary, and industry
must carefully consider the pros and cons of participation in
a transparent, centralized banking mechanism. Because indus-
try is focused on delivering clinical applications and must work
closely with regulatory authorities to do so, commercial compa-
nies are uniquely poised to create and support banks of high-
quality, clinical-grade hESCs and differentiated cell lines that
meet the strictest regulatory requirements.
Operational Challenges of Banking hESC Lines
Determining uniform banking policies and procedures that can
foster collaboration is complicated by the fact that the science
is rapidly evolving in an environment of heterogeneous laws,
guidelines, and ethical standards. The following is a review of
some of the challenging operational details that need to be
considered. These operational details are relevant to individual
freestanding local banks as well as to centralized banks.
Defining the Purpose and Scope of the Bank
It is first necessary to decidewhat types of cellswill be included in
the bank. Will the banking be limited to hESCs that are derived
from blastocysts? Or will pluripotent cells from alternate sources
such as amniotic fluid cells or reprogrammed somatic cells also
be included? Will any derivative products (i.e., derived cells) be
included as well? Will nonpluripotent stem cells be included?
Will the bank include only research-grade cells or also clinical-
gradecells?Next,whatwill be thestandards forbiological quality,
and how will the bank ascertain that banked cells meet those
standards? For example, what standard will the bank use to
routinely determine pluripotency and purity of the cell line?
Because there is noacceptedgold standard formanyof thesede-
terminations, both individual and centralized banks must clearly
state and justify what processes will be used and stand ready
tomodify their procedures in response tonewscientific evidence.
A local or a central bank can be narrow or broad in scope. If
different types or quality of cells are included, the bank will
have to develop a system that segregates the banking activities
as a function of cell type and quality. Investigators should expect
to request and receive cells that meet specific criteria. The more
heterogeneity of materials stored by the bank, the more onerous
the recordkeeping and logistics of running the business. A bank
with a broad scopemay provide a greater resource for investiga-
tors but at a higher operations cost. In contrast, a bank with a
narrow focus may be more efficiently run but of less value to
the broader community.
Determining Ethical Criteria for Banked Cells
The bankmust also decide whether or not specific ethical and/or
regulatory standards will be imposed on persons depositing
hESCs into the bank as well as persons accessing cells from
the bank. Both the regulations and the ethics are complicated
and open to much local interpretation. Specific ethical issues in-
clude, for example, the following: themoral status of the embryo;
the use of somatic cell nuclear transfer (SCNT) to derive hESC
lines; the interaction with gamete and embryo donors regarding
concerns relating to matters such as compensation, consent,310 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.privacy; and also some uses of resultant hESCs, especially in
terms of chimeras. Recognition of the need to thoughtfully
address these issues encouraged the development of guidelines
(such as NAS and ISSCR). While the existing guidelines recom-
mend standards, it is important to note that these are voluntary
and open to local interpretation and implementation.
In addition to guidelines, there are a variety of country, state,
and local laws that directly or indirectly pertain to hESC research.
There are new laws written in response to the emergence of this
research. There are old abortion and IVF laws that, because of
their construct, have an impact on hESC research. Although
the regulations and guidelines are a heterogeneous mix, they
are consistent in their mandate that materials from which hESCs
are derived be procured in an ethical and responsiblemanner. To
that end, most address, for example, recruitment of embryo,
gamete, and somatic cell donors and creation of an embryo by
fertilization or SCNT for the sole intent of using it for research.
An investigator deriving and/or using hESCsmust comply with
local law and local interpretation of guidance. Confusion and
problems arise when a hESC investigator wants to work with
an investigator from another locale that has different laws and/
or different interpretation of guidance. While a problem for any
collaboration, it is a major problem for banking activities.
It is incumbent on any hESC bank to have transparent policies
regarding how the bank will handle the ethical and regulatory
aspects of this research. Banks can take different approaches.
A bank could assume local laws and guidance interpretations
and only accept cells that were derived in compliancewith these.
A requesting researcher would then have to determine if the
bank’s standardmeets his/her local requirements. This approach
is efficient but could limit the availability of cells to requestors
operating under similar standards. Or a bank could attempt to
develop standards that are consistent with the most protective
jurisdictions. Alternatively, a bank could decide to accept lines
developed under a variety of standards and categorize hESCs
according to specific ethical and regulatory standards of different
countries and states. In this scenario, requesting researchers
would have the ability to identify and request cells that were in
compliance with their own local ethical and legal standards.
It seems that centralized banks would be more inclined to
implement the last approach. This does not mean that a central-
ized bank would be obligated to accept ‘‘any and all’’ cells: the
bank would likely identify some nonnegotiable requirements,
thus establishing a common denominator for the content of the
bank (but with more flexibility than option two); for example,
requiring that the derivation of deposited cell lines was approved
by an ethical review board or a stem cell research oversight
(SCRO) process as suggested by the ISSCR guidelines ensuring
the absence of coercion in the procurement process, identifying
elements that must be included in consent forms, etc.
At the present time, most hESC lines are considered ‘‘anony-
mous’’ in that they have no identifiers and no link back to specific
donors. This may change for several reasons, including, for
example, the emergence of clinical-grade hESCs with consider-
ation of traceability of the tissue donor(s), and also the increasing
use of PGD embryos, which may simply be difficult to anonym-
ize. The inclusion of any ‘‘identifiable’’ cell lines in a bank will
require processes for protecting the confidentiality of donors.
In addition, if relevant, consent forms will have to include the
Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 311
Cell Stem Cell
Commentaryfact that personal information will be linked to resultant hESC
lines. Carefully navigating issues related to the privacy of the
information stored in hESC banks will be critical to ensuring
public trust in the banking enterprise.
While defining any ethical and regulatory floor will be a prodi-
gious undertaking, once the floor has been determined, banks
must also develop processes for implementation. An example
of an ethical decision that has significant implementation issues
is how much control, if any, donors should have regarding the
fate of the hESC lines that were derived from their tissue (Holm,
2005). There are two basic questions. First, would the bank ac-
cept hESCs that were derived from embryos or other material if
the persons donating the material stipulated in their consent
form that theywanted to be able to direct the use of resultant lines
to specific types of research? If such hESCs would be accepted,
the bankwould need amechanism to deliver on this promise. The
second issue is the ability to withdraw from the research. If
donated materials were anonymized prior to hESC derivation,
withdrawal of hESCs would be logistically impossible. But, if a
particular hESC line remains linked to the identity of a donor or
donors, and the donor(s) withdraws consent, what will happen
to any resulting hESC line? The bank could decide that any resul-
tant hESCswill be destroyed—or, conversely, the bank could de-
cide that withdrawal applies only to the donatedmaterials and not
to resultant hESC lines. In either case, thebank shouldproactively
develop policies to address these unlikely but difficult situations.
Handling Procured Materials
One of the main benefits of centralized hESC banking is to re-
move from investigators the burdens of propagating adequate
numbers of hESCs as well as maintaining and routinely evaluat-
ing the inventory for quality. Therefore, most hESC banks will
have to address the technical challenges related to all aspects
of cell culture, expansion, scale-up processes for widespread
distribution, and storage. The enormity of this task cannot be
stressed enough (Stacey and Auerbach, 2007). It is important
to note that in order for a particular hESC line to maintain its
integrity, it must be maintained, stored, and expanded under
certain conditions so that they do not lose their initially defined
characteristics that are seen in the earliest passages. Does the
bank have the skill to dissect and recover cells from the original
cell line? What processes will be put in place to ‘‘manufacture’’
batches of consistently identical cells hESCs over time? How
will they assure microbiological safety? What quality assurance
steps will be implemented?What validation assays will be used?
And these technological aspects of hESC research are rapidly
evolving: how will the bank identify and accommodate the most
current standards? For example, as cryopreservation protocols
are re-examined and improved to increase survival rate of
high-quality hESCs that do not easily differentiate or otherwise
change their characteristics upon thaw (Hunt, 2007), how will
the bank have the resources to assure that the most effective
techniques are being employed?
Although the authors write from the perspective of nonscien-
tists, the challenges involved in establishing best banking
practices in an evolving field are well appreciated. Those estab-
lishing banks would benefit from consulting the ‘‘experts’’ and
putting in mechanisms to course correct as standards advance.
Hopefully, the future will bring improvements in hESC culture
techniques, allowing an element of stability and predictability.Determining Criteria for Accession and Responsibilities
of the Requestor
The bankmust have rules regardingwho can access hESCs from
the bank. The bank could provide specimens to anyone who
asks, or it could develop eligibility criteria relating to the
requestor and/or proposed use of the cells. Requirements for re-
questors could include, for example, only providing cells to an
investigator at an institution that has an oversight process for
hESC research, such as an embryonic stem cell oversight com-
mittee (ESCRO). Another criterion could be that the requestors
provide documentation of expertise in handling hESCs or even
other cells in culture. But what standard should be used to
assess these criteria? And is it realistic for a bank to assume
the responsibility of policing these criteria? Will the bank have
any different process for investigators from academia versus
industry versus a government agency? Will the bank ask for ver-
ification that the proposed research is legal in the country and/or
state in which it will be conducted? Will the bank ask for a formal
documentation of local approval? Or will a promissory note from
the investigator suffice? Presumably, ultimate liability for the
legality of any use of hESCs received from a bank would lie
with the requestor of the cells and the individuals actually per-
forming the research or using the cells. However, the bank
providing the materials must establish clear parameters regard-
ing any internal screening and/or approval of a requestor’s pro-
posed uses that the bank will perform before releasing the cells.
Banks should consider to what extent their internal review and
oversight of proposed uses could increase their potential liability.
As any bank is developed, it would be helpful to meet with local
ethical oversight committees to determine which, if any, actions
of the bank would need formal committee approval. The relevant
committees would be the ethical review committee, such as an
institutional review board (IRB), and the hESC oversight commit-
tee, such as an ESCRO or SCRO.
Will the bank have a contract with the requestor requiring that
relevant results of any research be returned to the bank? If
researchprovides information regarding thecharacter of apartic-
ular cell line, this could be very helpful to the bank in terms of
labeling the cell line for future requestors. The return of research
results to tissue repositories is becoming the standard for some
non-hESC banks, such as the new NIH-supported Genome-
Wide Association Studies (GWAS) (U.S. Department of Health
and Human Services, http://grants.nih.gov/grants/gwas/index.
htm). But such an arrangement may not be reasonable to the
hESC researchers themselves. This raises issues of claims to
intellectual property (IP). If a discovery is made from a specific
cell line, who has IP rights to the discovery? The person who
did the subsequent research? The deriver of the hESCs? The
bank itself? These rules must be known up front to allow the
person deriving the cells to make an informed decision about
whether or not to use the services of the bank.
Business Questions
It costs money to run any bank, and the depositors as well as the
recipients should expect to pay for this service. The associated
costs will differ tremendously as a function of the involvement
of the bank. For example, a bank that independently character-
izes and/or manipulates the hESCs will have higher costs. There
are a number of ways to cover the costs. Obviously, one solution
would be to obtain outside funding from foundations,
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likely be asked to pay a fee for obtaining the hESCs: will this be to
cover costs of that specific transaction? Or more? Will deposi-
tors receive anything for providing their cells to the bank? Or
will depositors be expected to pay for having their cells managed
by the bank? Thought will need to be given to any local rules pro-
hibiting payment in exchange for human tissue (to the extent they
apply to hESC lines); these types of restrictions are fairly com-
mon but often contain exceptions for reasonable administrative
costs related to the transaction at issue. The bankmust also con-
sider the investment that it makes to any particular cell line, by
maintaining them in culture, intermittently assessing their bio-
logic status, and possibly generating more hESCs from the orig-
inal line. A bank that invests this amount of time and effort may
also expect exclusivity from the depositors and have themprom-
ise that she or he will use only this one bank as the banking
source for a specific cell line.
The rules of any bank will be determined to some degree by
who owns or controls the bank. The obvious options include
academia, industry, private foundation/organization, or agovern-
ment agency. There are benefits and challenges associated with
each of these. The cost of such an enterprise may require gov-
ernment ownership, but government involvement may invoke
certain requirements or limitations onto banking procedures
and policies that might not otherwise apply under private owner-
ship. For example, in the United States, the current restriction on
federal funding of research involving hESC lines created after
August 9, 2001, limits the content of a government-supported
national bank considerably. If controlled by private industry,
the issues of IP and potentially conflict of interest increase.
And if controlled by an academic entity, there is the question
of resources. And there is the concern that the bank could be
overly influenced by that academic center’s hESC researchers.
It would be important to have banking operations be distinct
from the goals and interests of local researchers. Ownership
by a private foundation/organization is attractive in that it may
facilitate neutrality and buy in, but the concern of both immediate
and long-term resources is not trivial.
Conclusion
Despite the numerous challenges to the creation of hESC banks,
any challenges are far outweighed by the potential benefits.
There are many reasons for supporting centralized hESC banks
that canservean international clientele. hESC research is aglobal
enterprise that begins at the local level. The resources needed to
further this research should be available to researchers through-
out the world. Centralized banks capitalize on the reality of econ-
omy of scale; the resources and expertise required for maintain-
ing and characterizing these cells are substantial. Maintaining
and routinely evaluating these cells for quality requires an invest-
ment of space, equipment, and personnel. Centralizing these
efforts at a single (or a few) site(s) is responsible use of these
resources. The availability of hESCs to many investigators would312 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.thus be maximized and would potentially focus the research on
the use of the hESCs themselves rather than the derivation pro-
cess or the validation and expansion processes.
While the scientific and ethical/legal standards of banked
materials raise a number of questions, comprehensive and
transparent banking activities help to inform the discussion
and create the necessary community to forge reasonable stan-
dards. A large centralized hESC banking enterprise would serve
a central role in the creation of uniform ethical and scientific stan-
dards, minimize the continuing emergence of local interpreta-
tions and standards, and ultimately enhance collaboration,
increasing the output of this new area of research. Whether or
not the many jurisdictions that oversee hESC banks will be
able to harmonize their technical and ethical standards remains
to be seen; however, it is indeed a worthy goal.
REFERENCES
Andrews, P.W. (2007). Nat. Biotechnol. 25, 803–816.
Ben-Yosef, D., Malcov, M., and Eiges, R. (2008). Mol. Cell. Endocrinol. 282,
153–158.
Brivanlou, A.H., Gage, F.H., Jaenisch, R., Jessel, T., Melton, D., and Rossant,
J. (2003). Science 300, 913–916.
Crook, J.M., Peura, T.T., Kravets, L., Bosman, A.G., Buzzard, J.J., Horne, I.,
Hentze, H., Dunn, N.R., Zweigerdt, R., Chua, F., et al. (2007). Cell Stem Cell
1, 490–494.
Fuchs, D. (2004). The New York Times. February 15, 2004.
Guhra, A., Kurtza, A., Friedgenb, K., and Lo¨sera, P. (2006). Stem Cells 24,
2187–2191.
Healy, L., Hunt, C., Young, L., and Stacey, G. (2005). Adv. Drug Deliv. Rev. 57,
1981–1988.
Healy, L.E., Ludwig, T.E., and Choo, A. (2008). Cell StemCell 2, this issue, 305–
306.
Holm S. (2005). (http://www.eurostemcell.org/Documents/Ethics/Soren_
Holm.pdf)
Hunt, C. (2007). Transfus. Med. Hemother. 34, 293–304.
International Society for Stem Cell Research (2007). (http://www.isscr.org/
guidelines/index.htm)
Nakajima, F., Tokunaga, K., and Nakatsuji, N. (2007). Stem Cells 25, 983–985.
Nieto, N., Cobo, F., Barroso-deljesu´s, A., Barnie, A.H., Catalina, P., Cabrera,
C.M., Cortes, J.L., Montes, R.M., and Concha, A. (2006). Stem Cell Rev. 2,
117–126.
Sipp, D. (2007). Nature Reports Stem Cells. Published online November 8,
2007. 10.1038/stemcells.2007.117.
Stacey, G.N., and Auerbach, J.M. (2007). In Culture of Human Cells, R.I. Fresh-
ney, G.N. Stacey, and J.M. Auerbach, eds. (Hoboken, NJ: John Wiley and
Sons), pp. 1–21.
Taylor, C.J., Bolton, E.M., Pocock, S., Sharples, L.D., Pedersen, R.A., and
Bradley, J.A. (2005). Lancet 366, 2019–2025.
U.S. National Academy of Sciences (2005). Committee on Guidelines for
Human Embryonic Stem Cell Research. Guidelines for Human Embryonic
Stem Cell Research (Washington, DC: National Academies Press).
